|
Market Closed -
Nasdaq
16:00:00 2026-09-18 EDT
|
5-day change | 1st Jan Change | ||
| 0.3119 USD | -6.48% |
|
-2.65% | -68.81% |
| 09-02 | Needham Downgrades TScan Therapeutics to Hold From Buy | MT |
| 09-02 | Wedbush Downgrades TScan Therapeutics to Neutral From Outperform, Adjusts Price Target to $1 From $5 | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| TSCAN THERAPEUTICS, INC. | Bio Therapeutic Drugs | -6.48% | -2.65% | -68.81% | -81.87% | -95.00% | 22.6M |  | | |
- Stock Market
- Stocks
- TCRX Stock
- Charts TScan Therapeutics, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
